Dados B3 › LUXM4 × SCAR3
LUXM4 × SCAR3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | LUXM4 | SCAR3 | year |
|---|---|---|---|
| ROE | 14.1% | 4.9% | 2025 |
| ROIC | 13.5% | 2.6%! | 2025 |
| ROA | 10.1% | -1.6% | 2025 |
| Gross margin | 30.7% | 48.8% | 2025 |
| EBIT margin | 18.4% | 26.2% | 2025 |
| Net margin | 14.4% | -16.2% | 2025 |
| Net debt/EBITDA | -0.20x | 3.23x | 2025 |
| Current ratio | 1.79x | 1.78x | 2025 |
| Revenue growth (1y) | 15.8% | -41.1% | 2025 |
| Revenue growth (5y CAGR) | 8.6% | -2.6% | 2025 |
| Piotroski F-Score | 5/9 | 3/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | LUXM4 | SCAR3 | year |
|---|---|---|---|
| P/E | 7.29x | 12.57x | 2025 |
| P/B | 0.97x | 0.76x | 2025 |
| EV/EBITDA | 3.28x | 9.39x | 2025 |
| FCF yield | 5.2% | -21.2% | 2025 |
Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 10:04 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 10:04 UTC. If this does not match /saude, you are reading a cached copy.